今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

“币圈茅台”崩盘事件终迎和解，Terraform Labs及Do Kwon支付45亿美元罚款

纽约 - 2024年6月14日，曾搅动整个币圈的“币圈茅台”LUNA崩盘事件在美国暂时落下帷幕。纽约南区地方法院批准了美国证券交易委员会（SEC）与加密货币公司Terraform Labs及该公司首席执行官、LUNA币主要开发者Do Kwon达成的和解协议。根据协议，Do Kwon需向SEC支付45亿美元的罚金、预付利息和民事罚款，还面临一系列禁业等处罚。

LUNA的崩盘风波发生于2022年5月，当时与美元挂钩的虚拟货币稳定币Terra USD（UST）与姐妹代币LUNA在短短数天内双双崩盘，导致全球投资者约400亿美元损失。此次事件被认为是一场带有“庞氏骗局”意味的金融实验。

SEC在起诉书中指控Terraform Labs和Do Kwon欺骗投资者，并违反了美国证券法。SEC称，Terraform Labs虚假宣传了UST的稳定性，并操纵了LUNA的价格。

Do Kwon否认了所有指控，但他同意和解以避免诉讼带来的进一步风险。

LUNA崩盘事件对加密货币市场造成了巨大冲击，也引发了监管机构对加密货币行业的更多关注。美国、欧盟等多个国家和地区纷纷加强了对加密货币的监管力度。

以下是此次和解的一些重要细节：

• Do Kwon需向SEC支付10亿美元的罚款，35亿美元的预付利息和民事罚款。
• Do Kwon被禁止在未来三年内担任任何公开上市公司的董事或高管职务。
• Terraform Labs需向SEC支付2500万美元的罚款。

LUNA崩盘事件给投资者带来了深刻的教训，也警示了加密货币行业的潜在风险。投资者在投资加密货币时应审慎评估风险，选择合规的交易平台和产品。